NovaBay Pharmaceuticals, Inc. (NBY)
Pre-market:
- Business Wire
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
EMERYVILLE, Calif., May 03, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2024 after market close on Thursday, May 9, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
- Business Wire
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
EMERYVILLE, Calif., April 22, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces a new and enhanced marketing program that includes text message communications (SMS) and targeted email programs aimed at enhancing the Avenova® brand while engaging with customers to drive online sales of Avenova products. The new and enhanced programs build upon the Company’s past highly productive marketing pr
- Business Wire
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
EMERYVILLE, Calif., April 19, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that on April 18, 2024 it received a notice from the NYSE American LLC stating that the Company is below compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide pursuant to stockholders equity. The Company must submit a plan by May 18, 2024 advising of actions it has taken or will take to regain compliance with the
